CVP PHYSICIANS
Cincinnati Eye Institute

COMPLETED CLINICAL STUDIES

Past Anterior Segment & Glaucoma Trials

Bausch & Lomb – Trulign IOL #858 - Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber Intraocular Lens (IOL)

HumanOptics Iris Prosthesis FDA IDE Study – AI-001 – Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

Icon Bioscience – Protocol C15-01 - Evaluate the Safety of IBI-10090 for the Treatment of Inflammation Associated with Cataract Surgery

Visual Sciences – VS101-CS201 - Subconjunctival Latanoprost Insert for Glaucoma

Ocular Therapeutix – OTX-16-002 - Travoprost Punctum Plug Study for Glaucoma

Allergan – 192024-093 - A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension

Alcon – ILI875-C002 - A Prospective, Randomized, Controlled, Multi-Center Clinical Study of the ACRYSOF® IQ Extended Depth of Focus IOL

Alcon –COMPASS-XXT - An Observational Multicenter Clinical Study to Provide Additional Long-Term Follow-up Beyond 60 Months for Subjects Implanted with a CyPass Micro-Stent in the COMPASS Trial

Glaukos – GTS100-PAS2 - Post-Approval Study of the Glaukos® Istent® Trabecular Micro-Bypass Stent System in Conjunction with Cataract Surgery

InnFocus – Protocol INN-005 - A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShunt® Glaucoma Drainage System to Standard Trabeculectomy In Subjects with Primary Open Angle Glaucoma

Johnson & Johnson Surgical Vision – Protocols SUR-IOL-652-2002, SUR-CAT-652-2001, NXGT-201-TTL2, NXGT-202-QROS - Clinical Investigation of the Safety and Effectiveness of various Investigational Models of the TECNIS® Intraocular Lenses

University Hospitals Eye Institute - Genetic Susceptibility to Contact Lens Related Microbial Keratitis

Oculis - DX216 - Treatment of Inflammation and Pain Following Cataract Surgery

Emmes - Glaucoma outcomes survey study for MIGS devices for glaucoma patients

Tarsius – TRS01 – Post Surgical Inflammation following cataract surgery

Ocugen – OCU-310-301 - Safety and Efficacy Study of Brimonidine Tartrate 0.2% Nanoemulsion Eye Drops in Patients with Dry Eye Disease (DED).

Santen – DE117 - Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Once Daily and Twice Daily in Subjects with Primary Open-Angle Glaucoma or Ocular Hypertension

Kala Pharma – KPI-121-C-011 - Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease

Aerpio Pharma – AKB-9778-CI-OS-2001 - Study to Assess the Efficacy, Safety and Tolerability of Single or Twice Daily Doses of AKB-9778 Ophthalmic Solution as an Adjunct to Latanoprost in Patients with Ocular Hypertension (OHT) or Open Angle Glaucoma.

Novartis – CECF843A2201 - Study to evaluate the safety and efficacy of ECF843 vs Vehicle in subjects with dry eye disease.

FAES FARMA – 17-100-0012/BOFT-0218/AC-CAC - Study to Evaluate the Efficacy and Safety of Bilastine Ophthalmic Solution 0.6% Compared to Vehicle and Zaditen (Ketoifen Ophthalmic Solution 0.025%) for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (ORA-CAC®) Model.

Valeant Pharma – S0883 - Bioequivalence Study of the Generic Brinzolamide 1% Ophthalmic Suspension compared to Reference Listed Drug Azopt (Brinzolamide) Ophthalmic Suspension 1% in Subjects with Open-Angle Glaucoma or Ocular Hypertension.

CVP PHYSICIANS
Cincinnati Eye Institute

COMPLETED CLINICAL STUDIES

Past Retina Trials

Novartis (Protocol CRTH258B2301) Kestrel
Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema

Genentech (Protocol GR40548) Archway
Port Delivery System with Ranibizumab in patients with Neovascular Age-Related Macular Degeneration

Genentech (Protocol GR40349) Yosemite
Faricimab vs Lucentis in patients with diabetic macular edema

Chengdu (Protocol KHB-1801) Panda
Conbercept vs Eylea for intravitreal injection in subjects with neovascular age-related macular degeneration

Allergan (Protocol 1771-201-008) "Maple"
Evaluating Abicipar for Safety and Treatment Effect in Patients with Neovascular Age-related Macular Degeneration

Allergan (Protocol 150998-006) "SEQUOIA"
Abicipar vs Lucentis in patients with treatment-naïve CNV due to Wet AMD

Alcon (Protocol RTH258-C001) "HAWK"
RTH258 vs Eylea in patients with treatment-naïve CNV due to Wet AMD

F. Hoffmann La Roche/Genentech (Protocol GX29185) "SPECTRI" Phase III
Lampalizumab intravitreal injection vs sham in patients with Geographic Atrophy due to Dry AMD

Novartis (Protocol CLFG316a2203)
Intravitreal LFG316 in Patients With Geographic Atrophy Associated with Age-Related Macular Degeneration

Aerpio Therapeutics, Inc. (Protocol AKB-9778-CI-2003)
Safety and efficacy of daily, subcutaneous AKB-9778 injections as monotherapy or adjunctive therapy to ranibizumab vs. ranibizumab as monotherapy in patients with diabetic macular edema

Clearside Biomedical (Protocol CLS1003-301) "SAPPHIRE"
Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in RVO with ME

Thrombogenics (Protocol TG-MV-014) OASIS
Ocriplasmin Treatment For Symptomatic Vitreomacular Adhesion Including Macular Hole

Regeneron (Protocol HANDLE)
Intravitreal Aflibercept Injection for the Treatment of Choroidal Neovascularization Secondary to Presumed Ocular Histoplasmosis Syndrome

Ophthotech (Protocol OPH1002)
Fovista™ Administered In Combination With Lucentis® Compared To Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-related Macular Degeneration

Genentech (Protocol GX28228) Ladder
Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in patients with Subfoveal Neovascular Age-Related Macular Degeneration

Regeneron (Protocol Capella)
REGN2176-3 in patients with Neovascular Age-Related Macular Degeneration